Table 4.
Adjusted hazard ratios of non-persistence with time-varying covariates
| HRa (95% CI) | HRa (95% CI) | HRa (95% CI) | |
|---|---|---|---|
| Cohort | |||
| Warfarin | Reference | ||
| Apixaban | 0.76 (0.75–0.76) | 0.76 (0.76–0.77) | 0.62 (0.61–0.62) |
| Dabigatran | 1.23 (1.22–1.24) | 1.25 (1.23–1.26) | Reference |
| Rivaroxaban | 0.99 (0.98–0.99) | Reference | |
| Time-varying covariates | |||
| Stroke/SE (primary discharge) | 1.57 (1.53–1.61) | 1.58 (1.53–1.64) | 1.52 (1.45–1.60) |
| Major bleeding (primary discharge) | 2.96 (2.92–3.00) | 3.31 (3.25–3.37) | 3.12 (3.04–3.20) |
| New acute renal failure | 1.44 (1.42–1.46) | 1.45 (1.43–1.47) | 1.44 (1.41–1.47) |
| New chronic renal failure | 1.14 (1.12–1.15) | 1.17 (1.14–1.19) | 1.13 (1.10–1.16) |
| New cancer | 1.22 (1.20–1.25) | 1.23 (1.21–1.26) | 1.23 (1.19–1.27) |
| Cardioversions and catheter ablations | 1.17 (1.15–1.19) | 1.15 (1.13–1.18) | 1.13 (1.10–1.16) |
Data are presented as hazard ratio (95% confidence interval). All hazard ratios were significant at P < 0.001. Models adjusted for age, sex, region, atrial fibrillation index year, Deyo–Charlson Comorbidity Index, bleeding history, history of congestive heart failure, diabetes mellitus, hypertension, renal disease, liver disease, cancer, myocardial infarction, cardioversion and catheter ablations, dyspepsia or stomach discomfort, non-stroke/SE peripheral vascular disease, stroke/SE, transient ischemic attack, anemia and coagulation defects, alcoholism, peripheral artery disease, coronary artery disease, baseline medication use, and time-varying covariates during the follow-up
HR hazard ratio, CI confidence interval, SE systemic embolism